Laekna, Inc. (HK:2105) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Laekna, Inc. has reported significant advancements in their drug development programs, including the commencement of a Phase I clinical trial for their obesity treatment, LAE102, ahead of schedule, and the initiation of a Phase III trial for LAE002 in combination with fulvestrant for breast cancer. Both treatments have shown promise, with LAE002 demonstrating a well-tolerated safety profile and efficacy in prior studies, and the company plans to present further clinical data at upcoming medical conferences.
For further insights into HK:2105 stock, check out TipRanks’ Stock Analysis page.